Navigation Links
Immtech Investor Conference Call Scheduled for February 11, 2008
Date:2/6/2008

NEW YORK, Feb. 6 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) will have an investor conference call on Monday, February 11, 2008, at 4.30 PM (ET) to discuss its financial results for the quarter ended December 31, 2007 and to present an update on the Company's scientific and clinical progress. Investors and interested parties in the U.S. are invited to join the call by dialing (888) 338-8374 and callers outside the U.S. should call (706) 902-3163. The User Access Code is # 2167994. To register, please call no later than 10 minutes prior to the scheduled start of the call. A recording of the conference call will be available on the Company's website (http://www.immtechpharma.com) from February 12, 2008 to February 29, 2008.

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. ("Immtech") is a pharmaceutical company working to commercialize drugs to treat infectious diseases and is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), trypanosomiasis (HAT or African sleeping sickness), malaria and a well defined, expanding library of compounds targeting drug-resistant Gram-positive bacteria, fungal infections, Hepatitis C and other serious diseases. Immtech holds the exclusive worldwide licenses to certain patents, patent applications and technology for products derived from its proprietary pharmaceutical platform. For additional information, please visit Immtech's website at http://www.immtechpharma.com.

This press
'/>"/>

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine
2. Immtech to Present at The Bank of Montreal Healthcare Conference
3. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
5. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
6. PharmAthene to Present at the BIO CEO & Investor Conference 2008
7. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
8. Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12
9. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. Rigel to Present at BIO CEO & Investor Conference
11. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... leading provider of strategic communications services to corporations and organizations preparing ... the United States and Europe , ... returning to the firm,s Washington, D.C. office. ... two years of service as Associate Commissioner for the Office of ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... layer of carbon atoms, may be the most amazing ... yet lightweight and flexible, graphene enables electrons to flow ... conductor, combining electrical and optical functionalities in an exceptional ... sustainable carbon revolution, with profound impact in information and ...
... GeoVax Labs, Inc. (OTCBB: GOVX), a biotechnology company ... today released its 2010 Annual Report and President,s ... (10-K) provides information on the state of the ... his Letter, GeoVax,s President Robert T. McNally, Ph.D., ...
... 2011 Bacterin International Holdings, Inc. ("Bacterin") (NYSE Amex: ... today announced that its chairman and CEO, Guy Cook, will ... Conference at the Hard Rock Hotel in Hollywood, Florida, on ... At the time of the presentation, a live audio and ...
Cached Biology Technology:GRAPHENE-CA appointed an EU Future Emerging Technology flagship pilot 2GeoVax Labs Announces Availability of 2010 Annual Report and President's Letter to Stockholders 2Bacterin International to Present at Noble Financial Capital Markets' Seventh Annual Equity Conference on May 16, 2011 2
(Date:4/24/2014)... that the world,s oceans play a crucial role ... between Earth,s ecosystems and atmosphere. Now scientists at ... have taken a leap forward in understanding the ... use carbon dioxide to make new cells, a ... into the sea as a buffet of edible ...
(Date:4/24/2014)... NY, April 24, 2014GEN Publishing recently introduced ... publication focusing on the application of OMICs technologies ... next-gen sequencing, are beginning to transform medical care ... over the past decade-and-a-half. , "GEN,s editors and ... pharmacogenomics, genomics, metabolomics, transcriptomics, etc. etc. for years," ...
(Date:4/24/2014)... Scientific Reports journal. , CSIC researcher Carles Lalueza-Fox, ... CSIC and Pompeu Fabra University-UPF), explains: "When the Y chromosome ... it did not match with the DNA recovered from the ... and to make a functional interpretation in order to see ... , The functional genome analysis was based on two main ...
Breaking Biology News(10 mins):Microscopic organism plays a big role in ocean carbon cycling, Scripps scientists discover 2Microscopic organism plays a big role in ocean carbon cycling, Scripps scientists discover 3The blood preserved in the pumpkin did not belong to Louis XVI 2
... compared to last year,s record size. According to measurements made by ... tonnes, compared to the 2006 record ozone loss of 40 million ... the depth of the ozone hole. The area of this years ... Units is 24.7 million sq km, roughly the size of ...
... A team of UAB geneticists, doctors and biostatisticians has ... to study and test new treatments for neurofibromatosis, or ... a nine-institution group called the NF Consortium. The coalition ... manage multiple clinical trials held across the nation looking ...
... Keck School of Medicine of the University of Southern California ... T. & Eileen L. Norris Foundation that will be critical ... to the study of epigenetics. The grant will solidify ... holds great promise in the treatment and prevention of cancer, ...
Cached Biology News:2007 ozone hole 'smaller than usual' 22007 ozone hole 'smaller than usual' 3UAB wins $5.7M neurofibromatosis grant 2UAB wins $5.7M neurofibromatosis grant 3$10 million gift to support cutting-edge epigenome center at USC 2$10 million gift to support cutting-edge epigenome center at USC 3
... IVF are designed for human in vitro ... setup and operation, and convenience. Chamber, ... displayed on the control panel. Our signature ... by way of the thermal printer inside ...
Anti-VDAC (Voltage-Dependent Anion Channel) AVOID FREEZE/THAW CYCLES. Recognizes the porin 31HL protein. Corresponds to mAb 1 in the literature....
... Crotalus adamanteus venom Description: Phosphodiesterase ... used in studying nucleic acid ... It hydrolyzes 5'-mononucleotides from 3'-hydroxy-terminated ... Phosphodiesterase I cleaves ADP-ribosylated proteins ...
A powerful, easy-to-use solution, the SORVALL RC12BP Blood Processing System allows you to manufacture blood components quickly and cost-effectively while ensuring product quality, safety, and GMP co...
Biology Products: